Revlimid Hits Target in Newly Diagnosed Myeloma Patients
By Catherine Shaffer
Staff Writer
Staff Writer
Thursday, July 11, 2013
Celgene International Sarl's successful multiple myeloma drug, Revlimid (lenolidomide), met an important benchmark in newly diagnosed patients in a Phase III study.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries, please contact Tyler Beatty:
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter